EX-10.17 3 s101435_ex10-17.htm EXHBIT 10.17

 

Exhibit 10.17

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

AMENDMENT TO JOINT VENTURE FOR R&D AGREEMENT

 

This amendment to Joint Venture for R&D Agreement (this “Amendment”) is entered into as of March 12, 2015, by and between Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) and Intec Pharma Ltd. (“Company”) (each to be referred to as a “Party” and together as the “Parties”).

 

WHEREAS,the Parties entered into a Joint Venture for R&D Agreement on June 1, 2000, which was extended and amended on October 5, 2004 and July 13, 2005 (the agreement and its amendments shall be referred together in this Amendment as the “Agreement”); and

 

WHEREAS,in connection with the pending grant of a sublicense by the Company to Biogen Idec, the Parties wish to amend the Agreement as set forth herein, to become effective only with respect to such sublicense to be granted to Biogen Idec, as of the date such sublicense agreement is executed with Biogen Idec;

 

NOW, THEREFORE, the Parties hereto, intending to be legally bound, hereby agree as follows:

 

Except as specifically defined herein, all terms used in this Amendment shall have the meaning ascribed to them in the Agreement.

 

1.Amendment

 

Effective as of the date of this Amendment, the Agreement shall be amended as follows:

 

1.1Section 2 of Appendix E of the Agreement shall be amended to read as follows:

 

“The Company will pay Yissum Sublicense Fees during the Royalty Term at a rate of 15% of all Sublicense Consideration.”

 

1.2The following definitions will be added to Appendix E of the Agreement:

 

Royalty Term” means, on a country-by-country basis, a period of 15 years from the date of the First Commercial Sale in each country.

 

Sublicense Consideration” shall mean any proceeds or consideration or benefit of any kind whatsoever that the Company or its Affiliate receives from a Sublicensee to the extent that such is a direct result of the grant of a Sublicense or an option to obtain such Sublicense, other than research and development funding that is actually used to cover the actual cost for research and development of a Product performed under the Sublicense agreement.

 

1.3The term “Distributor” and all references thereto (including within the Net Sales definition) shall be deleted.

 

1.4The term “Product” shall be amended to read as follows:

 

“Product” shall mean any product, process or service, the development, manufacture or sale of which exploits, comprises, contains, incorporates, is related to, or based on any of the patents and/or patent applications set forth in Exhibit 1.4 attached hereto.

 

1.5The Parties acknowledge and agree that (i) the patent applications and patents set forth on Exhibit 1.5(a) are solely owned by Yissum and are subject to an exclusive license by Yissum to the Company pursuant to the Agreement; and (ii) the Company is the sole and exclusive owner of the patents and/or patent applications set forth in Exhibit 1.5(b) and all inventions disclosed or claimed in such patents and patent applications (collectively, “Intec Technology”) and Yissum acknowledges that it has no ownership right or interest in or claim with respect to such Intec Technology apart from the right to receive Royalties and Sublicense Fees as provided in the Agreement.

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

1.6Section 6(f) of the Agreement shall be amended to read as follows:

 

“Any Sublicensee may sublicense the rights granted to such Sublicensee by the Company through multiple tiers without notice to or consent of Yissum, provided that such Sublicensee is Biogen Idec.”

 

1.7The following Section 15(f) shall be added to the Agreement:

 

“15(f). In the event that the Agreement is terminated for any reason whatsoever, then, at the request of Biogen Idec, if it is not then in material default of the applicable Sublicense, Yissum shall enter into a new license agreement with Biogen Idec on substantially the same terms as Biogen Idec, provided, however, that such terms shall be amended, if necessary, to the extent required to ensure that such new agreement does not impose any obligations or liabilities on Yissum which are not included in or are greater in scope than Yissum’s obligations or liabilities under this Agreement”

 

1.8Yissum acknowledges and agrees that, notwithstanding the provisions of Section 6(e), Section 6(f) and Section 11(f) of the Agreement, Biogen Idec nor a Sub-sublicensee of Biogen Idec shall be required to enter into any direct undertaking or agreement of any kind with Yissum.

 

2.Effectiveness of Amended Agreement

 

The Agreement, as amended hereby, shall continue in full force and effect as originally constituted and is hereby ratified and affirmed by the Parties.

 

IN WITNESS WHEREOF, the parties have caused this Third Amendment to be executed by their duly authorized representatives as of the date first written above.

 

Yissum Research and Development   Intec Pharma Ltd.
Company of the Hebrew University    
of Jerusalem Ltd.    
     
By: /s/ Yaacov Michlin and Shoshi Keynan   By: /s/ Zeev Weiss
         
Name:

Yaacov Michlin – CEO and

Shoshi Keynan – VP Licensing, Pharmaceuticals

  Name: Zeev Weiss
         
Title:     Title:  

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

Exhibit 1.4

 

1.PatentYissum Research Development Company of the Hebrew University of Jerusalem Gastroretentive
Controlled Release Pharmaceutical Dosage Forms -(Client Case:IN-1-IL) - (0047465)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
Israel   149853   1634914   20/11/2000   149853   01/04/2007   20/11/2018
Patent Cooperation Treaty   PCT/IL00/00774   1635077   20/11/2000   WO 01/37812   31/05/2001    
Australia   16477/01   1635101   20/11/2000   783062   05/01/2006   20/11/2015
Canada   2,392,361   1635119   20/11/2000   2,392,361   19/01/2010   20/11/2015
Japan   2001-539427   1635127   20/11/2000   4679020   10/02/2011   10/02/2015
United  States of America   10/157,325   1635143   20/11/2000   6,685,962   03/02/2004   03/08/2015
South Africa   200204268   1635150   20/11/2000   2002/4268   26/11/2003   20/11/2015
European Patent Office   00978993.4   1635168   20/11/2000   1235557   27/07/2005    
France   00978993.4   1635572   20/11/2000   1235557   27/07/2005   30/11/2015
Germany   00978993.4   1635580   20/11/2000   60021604   27/07/2005   30/11/2015
Spain   00978993.4   1635598   20/11/2000   1235557   27/07/2005   30/11/2015
Switzerland   00978993.4   1635606   20/11/2000   EP1235557   27/07/2005   30/11/2015
Ireland   00978993.4   1635630   20/11/2000   1235557   27/07/2005   30/11/2015
Italy   00978993.4   1635648   20/11/2000   1235557   27/07/2005   30/11/2015
United Kingdom   00978993.4   1635655   20/11/2000   1235557   27/07/2005   30/11/2015

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

2.PatentIntec Pharma Ltd.
Method and Apparatus for Forming Delivery Devices for Oral Intake of an Agent -(Client Case:IN-3-USP) -(0047512)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   60/759,554   1636661   18/01/2006            
Patent Cooperation Treaty   IL2007/000070   1724418   18/01/2007   WO2007/083309   26/07/2007    
European Patent Office   07700757.3   1853217   18/01/2007   1981465   22/10/2008   31/01/2015
Canada   2,637,655   1853225   18/01/2007           18/01/2015
Israel   192896   1853233   18/01/2007   192896   28/09/2013   18/01/2017
Japan   2008-550909   1853241   18/01/2007   5399715   01/11/2013   01/11/2016
United States of America   12/087,888   1853258   18/01/2007   8,298,574   30/10/2012   30/04/2016
United States of America   13/613,718   2181500   18/01/2007   8,753,678   17/06/2014   17/12/2017
United States of America   13/800,471   2214433   18/01/2007   8,609,136   17/12/2013   17/06/2017
Japan   2013-054912   2216375   18/01/2007   2013-129669   04/07/2013    
Israel   226561   2228767   18/01/2007            
Israel   226563   2229192   18/01/2007            
Israel   226564   2229205   18/01/2007            
United                        
States of America   14/305,600   2275337   18/01/2007  

US-2014-

0360132

  11/12/2014    

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

3.PatentIntec Pharma Ltd.
A Gastro-Retentive System for the Delivery of Macromolecules -(Client Case:IN-4-USP) -(0047513)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   60/773,316   1636679   15/02/2006            
Patent Cooperation Treaty   IL2007/000212   1731967   15/02/2007   WO 2007/093999   23/08/2007    
European Patent Office   07713260.3   1859727   15/02/2007   1991210   19/11/2008   28/02/2015
Canada   2,642,479   1859735   15/02/2007   2,642,479   19/08/2014   15/02/2015
Israel   193450   1859743   15/02/2007            
United States of
America
  12/223,965   1859750   15/02/2007  

US-2009-

0304768

  10/12/2009    

 

4.PatentIntec Pharma Ltd.
Carbidopa/Lipodopa Gastroretentive Drug Delivery -(Client Case:IN-7-IL) -(060812)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
Israel   208708   2051008   17/04/2009            

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

4.PatentIntec Pharma Ltd.
Carbidopa/Lipodopa Gastroretentive Drug Delivery -(Client Case:IN-7-IL) -(060812)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   12/937,955   2144590   17/04/2009   8,771,730   08/07/2014   08/01/2018
Patent Cooperation Treaty   PCT/IB2009/005691   2153336   17/04/2009   WO 2009/144558        
Canada   2,721,493   2153341   17/04/2009           17/04/2015
China   200980120103.9   2153353   17/04/2009   CN102149369A   10/08/2011    
European Patent Office   09754186.6   2153363   17/04/2009   2276473   26/01/2011   30/04/2015
India   7638/DELNP/2010   2153372   17/04/2009            
Japan   2011-504573   2153395   17/04/2009            
Japan       2330464                
Republic of Korea   10-2010-7025481   2153405   17/04/2009            
South Africa   2010/07797   2153411   17/04/2009   2010/07797   27/07/2011   17/04/2015
Hong Kong   11113197.1   2153823   17/04/2009   1158545   20/07/2012   17/04/2018
United States of America   14/322,436   2286884   17/04/2009  

US-2014-

0314842

  23/10/2014    
United States of America   14/322,460   2286894   17/04/2009  

US-2015-

0010624

  08/01/2015    

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

5.PatentIntec Pharma Ltd.
ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM -(Client Case:IN-8-IL) -(060811)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
Israel   213376   2127779   19/10/2009            
Patent Cooperation Treaty   PCT/IB2009/007731   2153230   19/10/2009   WO 2010/064139        
China   200980153943.5   2153258   19/10/2009   CN102300463A   28/12/2011   19/10/2014
European Patent Office   09830077.5   2153268   19/10/2009   2378883   26/10/2011   31/10/2014
India   5067/DELNP/2011   2153278   19/10/2009            
South Africa   2011/04620   2153314   19/10/2009   2011/04620   28/03/2012   19/10/2015
United States of America   13/132,899   2153326   19/10/2009  

US-2012-

0021051

  26/01/2012    
Japan   2014-231788   2320509   19/10/2009            

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

6.PatentIntec Pharma Ltd.
Accordion pill comprising levodopa for an improved treatment of Parkinson’s Disease symptoms -(Client Case:IN-11-USP) -(060810)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   61/408,985   2153012   01/11/2010            

Patent Cooperation Treaty

  PCT/IB2011/002888   2153034   01/11/2011   WO 2012/059815   10/05/2012    
Canada   2,815,959   2222633   01/11/2011           01/11/2015
European Patent Office   11805936.9   2222641   01/11/2011   2635272   11/09/2013   30/11/2015
India   4158/DELNP/2013   2222652   01/11/2011            
Israel   226000   2222662   01/11/2011            
United States of America   13/882,768   2222675   01/11/2011  

US-2014-

0017303

  16/01/2014    

 

7.PatentIntec Pharma Ltd.
“[***]”
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
“[***]”   “[***]”   “[***]”   “[***]”            

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

8.PatentIntec Pharma Ltd.
“[***]”
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
“[***]”   “[***]”   “[***]”   “[***]”            

 

9.PatentIntec Pharma Ltd.
“[***]”
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
“[***]”   “[***]”   “[***]”   “[***]”            

 

10.PatentIntec Pharma Ltd.
“[***]”
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
“[***]”   “[***]”   “[***]”   “[***]”            

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

Exhibit 1.5 (a)

 

1.PatentYissum Research Development Company of the Hebrew University of Jerusalem Gastroretentive Controlled Release Pharmaceutical Dosage Forms -(Client Case:IN-1-IL) - (0047465)  

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
Israel   149853   1634914   20/11/2000   149853   01/04/2007   20/11/2018
Patent Cooperation Treaty   PCT/IL00/00774   1635077   20/11/2000   WO 01/37812   31/05/2001    
Australia   16477/01   1635101   20/11/2000   783062   05/01/2006   20/11/2015
Canada   2,392,361   1635119   20/11/2000   2,392,361   19/01/2010   20/11/2015
Japan   2001-539427   1635127   20/11/2000   4679020   10/02/2011   10/02/2015
United States of America   10/157,325   1635143   20/11/2000   6,685,962   03/02/2004   03/08/2015
South Africa   200204268   1635150   20/11/2000   2002/4268   26/11/2003   20/11/2015
European Patent Office   00978993.4   1635168   20/11/2000   1235557   27/07/2005    
France   00978993.4   1635572   20/11/2000   1235557   27/07/2005   30/11/2015
Germany   00978993.4   1635580   20/11/2000   60021604   27/07/2005   30/11/2015
Spain   00978993.4   1635598   20/11/2000   1235557   27/07/2005   30/11/2015
Switzerland   00978993.4   1635606   20/11/2000   EP1235557   27/07/2005   30/11/2015
Ireland   00978993.4   1635630   20/11/2000   1235557   27/07/2005   30/11/2015
Italy   00978993.4   1635648   20/11/2000   1235557   27/07/2005   30/11/2015
United Kingdom   00978993.4   1635655   20/11/2000   1235557   27/07/2005   30/11/2015

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

Exhibit 1.5 (b)

 

2.PatentIntec Pharma Ltd.
Method and Apparatus for Forming Delivery Devices for Oral Intake of an Agent -(Client Case:IN-3-USP) -(0047512)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United  States of  America   60/759,554   1636661   18/01/2006            
Patent Cooperation Treaty   IL2007/000070   1724418   18/01/2007   WO2007/083309   26/07/2007    
European Patent Office   07700757.3   1853217   18/01/2007   1981465   22/10/2008   31/01/2015
Canada   2,637,655   1853225   18/01/2007           18/01/2015
Israel   192896   1853233   18/01/2007   192896   28/09/2013   18/01/2017
Japan   2008-550909   1853241   18/01/2007   5399715   01/11/2013   01/11/2016
United States of America   12/087,888   1853258   18/01/2007   8,298,574   30/10/2012   30/04/2016
United States of  America   13/613,718   2181500   18/01/2007   8,753,678   17/06/2014   17/12/2017
United States of America   13/800,471   2214433   18/01/2007   8,609,136   17/12/2013   17/06/2017
Japan   2013-054912   2216375   18/01/2007   2013-129669   04/07/2013    
Israel   226561   2228767   18/01/2007            
Israel   226563   2229192   18/01/2007            
Israel   226564   2229205   18/01/2007            
United States of America   14/305,600   2275337   18/01/2007  

US-2014-0360132

11/12/2014    

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

3.PatentIntec Pharma Ltd.
A Gastro-Retentive System for the Delivery of Macromolecules -(Client Case:IN-4-USP) -(0047513)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   60/773,316   1636679   15/02/2006            
Patent Cooperation Treaty   IL2007/000212   1731967   15/02/2007   WO2007/093999   23/08/2007    
European Patent Office   07713260.3   1859727   15/02/2007   1991210   19/11/2008   28/02/2015
Canada   2,642,479   1859735   15/02/2007   2,642,479   19/08/2014   15/02/2015
Israel   193450   1859743   15/02/2007            
United States of America   12/223,965   1859750   15/02/2007  

US-2009-0304768

  10/12/2009    

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

4.PatentIntec Pharma Ltd.
Carbidopa/Lipodopa Gastroretentive Drug Delivery -(Client Case:IN-7-IL) -(060812)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
Israel   208708   2051008   17/04/2009            
United States of America   12/937,955   2144590   17/04/2009   8,771,730   08/07/2014   08/01/2018
Patent Cooperation Treaty   PCT/IB2009/005691   2153336   17/04/2009   WO2009/144558        
Canada   2,721,493   2153341   17/04/2009           17/04/2015
China   200980120103.9   2153353   17/04/2009   CN102149369A   10/08/2011    
European Patent Office   09754186.6   2153363   17/04/2009   2276473   26/01/2011   30/04/2015
India   7638/DELNP/2010   2153372   17/04/2009            
Japan   2011-504573   2153395   17/04/2009            
Japan       2330464                
Republic of Korea   10-2010-7025481   2153405   17/04/2009            
South Africa   2010/07797   2153411   17/04/2009   2010/07797   27/07/2011   17/04/2015
Hong Kong   11113197.1   2153823   17/04/2009   1158545   20/07/2012   17/04/2018
United States of  America   14/322,436   2286884   17/04/2009  

US-2014-0314842

  23/10/2014    

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

4.PatentIntec Pharma Ltd.
Carbidopa/Lipodopa Gastroretentive Drug Delivery -(Client Case:IN-7-IL) -(060812)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   14/322,460   2286894   17/04/2009  

US-2015-0010624

  08/01/2015    

 

5.PatentIntec Pharma Ltd.
ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM -(Client Case:IN-8-IL) -(060811)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
Israel   213376   2127779   19/10/2009            

Patent Cooperation Treaty

  PCT/IB2009/007731   2153230   19/10/2009   WO2010/064139        
China   200980153943.5   2153258   19/10/2009   CN102300463A   28/12/2011   19/10/2014
European Patent Office   09830077.5   2153268   19/10/2009   2378883   26/10/2011   31/10/2014
India   5067/DELNP/2011   2153278   19/10/2009            
South Africa   2011/04620   2153314   19/10/2009   2011/04620   28/03/2012   19/10/2015

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

5.PatentIntec Pharma Ltd.
ZALEPLON GASTRORETENTIVE DRUG DELIVERY SYSTEM -(Client Case:IN-8-IL) -(060811)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   13/132,899   2153326   19/10/2009  

US-2012-0021051

  26/01/2012    
Japan   2014-231788   2320509   19/10/2009            

 

6.PatentIntec Pharma Ltd.
Accordion pill comprising levodopa for an improved treatment of Parkinson’s Disease symptoms -(Client Case:IN-11-USP) -(060810)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   61/408,985   2153012   01/11/2010            
Patent Cooperation Treaty   PCT/IB2011/002888   2153034   01/11/2011   WO2012/059815   10/05/2012    
Canada   2,815,959   2222633   01/11/2011           01/11/2015
European Patent Office   11805936.9   2222641   01/11/2011   2635272   11/09/2013   30/11/2015
India   4158/DELNP/2013   2222652   01/11/2011            
Israel   226000   2222662   01/11/2011            

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

6.PatentIntec Pharma Ltd.
Accordion pill comprising levodopa for an improved treatment of Parkinson’s Disease symptoms -(Client Case:IN-11-USP) -(060810)
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
United States of America   13/882,768   2222675   01/11/2011  

US-2014-

0017303

  16/01/2014    

 

7.PatentIntec Pharma Ltd.
“[***]”
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
“[***]”   “[***]”   “[***]”   “[***]”            

 

8.PatentIntec Pharma Ltd.

“[***]”

 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
“[***]”   “[***]”   “[***]”   “[***]”            

  

9.Patent Intec Pharma Ltd.
“[***]”
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
“[***]”   “[***]”   “[***]”   “[***]”            

 

 
 

 

NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF THE REDACTED LANGUAGE.

 

10.PatentIntec Pharma Ltd.
“[***]”
 

 

Country   App. No.   Our 
Ref.
  Filed   Patent No./ 
Publication No.
  Grant Date/ 
Pub. Date
  Next Renewal
“[***]”   “[***]”   “[***]”   “[***]”